234 related articles for article (PubMed ID: 25953102)
1. Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9.
Chau D; Ng K; Chan TS; Cheng YY; Fong B; Tam S; Kwong YL; Tse E
J Hematol Oncol; 2015 May; 8():46. PubMed ID: 25953102
[TBL] [Abstract][Full Text] [Related]
2. Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells.
Leung J; Pang A; Yuen WH; Kwong YL; Tse EW
Blood; 2007 Jan; 109(2):740-6. PubMed ID: 16968895
[TBL] [Abstract][Full Text] [Related]
3. 19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia.
Kumagai T; Shih LY; Hughes SV; Desmond JC; O'Kelly J; Hewison M; Koeffler HP
Cancer Res; 2005 Mar; 65(6):2488-97. PubMed ID: 15781666
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine.
Wu XX; Ogawa O; Kakehi Y
Int J Oncol; 2004 Jun; 24(6):1489-97. PubMed ID: 15138592
[TBL] [Abstract][Full Text] [Related]
5. Carbonyl reductase 1 offers a novel therapeutic target to enhance leukemia treatment by arsenic trioxide.
Jang M; Kim Y; Won H; Lim S; K R J; Dashdorj A; Min YH; Kim SY; Shokat KM; Ha J; Kim SS
Cancer Res; 2012 Aug; 72(16):4214-24. PubMed ID: 22719067
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
Yan H; Peng ZG; Wu YL; Jiang Y; Yu Y; Huang Y; Zhu YS; Zhao Q; Chen GQ
Haematologica; 2005 Dec; 90(12):1607-16. PubMed ID: 16330433
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antitumor activity of oridonin and arsenic trioxide on hepatocellular carcinoma cells.
Chen G; Wang K; Yang BY; Tang B; Chen JX; Hua ZC
Int J Oncol; 2012 Jan; 40(1):139-47. PubMed ID: 21947421
[TBL] [Abstract][Full Text] [Related]
8. 5-azacytidine enhances efficacy of multiple chemotherapy drugs in AML and lung cancer with modulation of CpG methylation.
Füller M; Klein M; Schmidt E; Rohde C; Göllner S; Schulze I; Qianli J; Berdel WE; Edemir B; Müller-Tidow C; Tschanter P
Int J Oncol; 2015 Mar; 46(3):1192-204. PubMed ID: 25501798
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide inhibits DNA methyltransferase and restores TMS1 gene expression in K562 cells.
Li H; Wang Y; Xu W; Dong L; Guo Y; Bi K; Zhu C
Acta Haematol; 2015; 133(1):18-25. PubMed ID: 24993472
[TBL] [Abstract][Full Text] [Related]
10. Effects of arsenic trioxide administration styles on leukocytosis.
Zhou J; Meng R; Sui XH; Meng L; Yang BF
Chin Med Sci J; 2006 Jun; 21(2):111-4. PubMed ID: 16845799
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide suppresses thymidylate synthase in 5-FU-resistant colorectal cancer cell line HT29 In Vitro re-sensitizing cells to 5-FU.
Subbarayan PR; Lee K; Ardalan B
Anticancer Res; 2010 Apr; 30(4):1157-62. PubMed ID: 20530422
[TBL] [Abstract][Full Text] [Related]
12. Trolox enhances the anti-lymphoma effects of arsenic trioxide, while protecting against liver toxicity.
Diaz Z; Laurenzana A; Mann KK; Bismar TA; Schipper HM; Miller WH
Leukemia; 2007 Oct; 21(10):2117-27. PubMed ID: 17690699
[TBL] [Abstract][Full Text] [Related]
13. Effects of arsenic trioxide (As2O3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of resistance.
Lehmann S; Bengtzen S; Paul A; Christensson B; Paul C
Eur J Haematol; 2001 Jun; 66(6):357-64. PubMed ID: 11488934
[TBL] [Abstract][Full Text] [Related]
14. Aquaporin 9, a promising predictor for the cytocidal effects of arsenic trioxide in acute promyelocytic leukemia cell lines and primary blasts.
Iriyama N; Yuan B; Yoshino Y; Hatta Y; Horikoshi A; Aizawa S; Takeuchi J; Toyoda H
Oncol Rep; 2013 Jun; 29(6):2362-8. PubMed ID: 23563754
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide re-sensitizes ERα-negative breast cancer cells to endocrine therapy by restoring ERα expression in vitro and in vivo.
Zhang W; Wang L; Fan Q; Wu X; Wang F; Wang R; Ma Z; Yang J; Lu SH
Oncol Rep; 2011 Sep; 26(3):621-8. PubMed ID: 21687957
[TBL] [Abstract][Full Text] [Related]
16. Significance of intracellular arsenic trioxide for therapeutic response in acute promyelocytic leukemia.
Sahu GR; Jena RK
Am J Hematol; 2005 Feb; 78(2):113-6. PubMed ID: 15682419
[TBL] [Abstract][Full Text] [Related]
17. [The expression of AQP9 in HepG2 cells affects cell biological behaviors and sensitivity to As2O3].
Tang J; Wang C; Jiang Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Jun; 31(6):769-74. PubMed ID: 26062419
[TBL] [Abstract][Full Text] [Related]
18. Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias.
Tabellini G; Tazzari PL; Bortul R; Evangelisti C; Billi AM; Grafone T; Martinelli G; Baccarani M; Martelli AM
Br J Haematol; 2005 Sep; 130(5):716-25. PubMed ID: 16115127
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide downregulates the expression of annexin II in bone marrow cells from patients with acute myelogenous leukemia.
Zhang XH; Hu Y; Bao L; Jiang Q; Yang LH; Lu XJ; Hong M; Xia LH; Guo T; Shen GX; Zhu HH; Zhao T; Song SJ
Chin Med J (Engl); 2009 Sep; 122(17):1969-73. PubMed ID: 19781379
[TBL] [Abstract][Full Text] [Related]
20. Granulocyte colony-stimulating factor potentiates differentiation induction by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in the acute promyelocytic leukemia cell line HT93A.
Iriyama N; Yuan B; Hatta Y; Horikoshi A; Yoshino Y; Toyoda H; Aizawa S; Takeuchi J
Oncol Rep; 2012 Nov; 28(5):1875-82. PubMed ID: 22940758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
